AbbVie Inc. — Form 8-K
Filed July 6, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 18/100
What the filing says
AbbVie incurred $291M in acquired in-process R&D (IPR&D) and milestone expenses in Q2 2026, reducing adjusted diluted EPS guidance by $0.17 per share for both Q2 and full-year 2026. Full-year adjusted diluted EPS guidance revised to $13.91–$14.11 (from $14.08–$14.28 previously). The company excludes any additional IPR&D and milestone expenses beyond Q2 2026 from guidance as they cannot be reliably forecasted.
Why this rating
$291M IPR&D charge is ~0.09% of $325B market cap; routine R&D amortization, immaterial to trajectory.
See more from July 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.